Dr. Callander is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-265-1700Fax+1 608-266-6020
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1988 - Present
WI State Medical License 2004 - 2025
TX State Medical License 1995 - 2024
GA State Medical License 1989 - 1989- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma Start of enrollment: 2006 Nov 01
- Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma Start of enrollment: 2004 Feb 01
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
- Join now to see all
Publications & Presentations
PubMed
- 98 citationsLonger term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka
Cancer. 2021-07-27 - 77 citationsTPL2 kinase regulates the inflammatory milieu of the myeloma nicheChelsea Hope, Samuel J. Ollar, Erika Heninger, Ellen Hebron, Jeffrey L. Jensen
Blood. 2014-05-22 - 629 citationsDaratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M. Weiss, Saad Z. Usmani, Seema Singhal, Ajai Chari
Lancet. 2016-04-09
Abstracts/Posters
- Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid LeukemiaNatalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple MyelomaNatalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
COVID-19 Vaccines Are Safe for People with Cancer, Researchers SayFebruary 7th, 2022- COVID mRNA Vaccine Equally Safe for People with CancerFebruary 7th, 2022
- Multiple Myeloma: Choosing Your PathDecember 18th, 2020
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
